(Q36631430)

15 August 2017

1 reference

title

Novel signal transduction pathways: analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

15 August 2017

main subject

0 references

author name string

Atreya R

series ordinal

1

1 reference

15 August 2017

Atreya I

series ordinal

2

1 reference

15 August 2017

Neurath MF

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Annals of the New York Academy of Sciences

15 August 2017

published in

1 reference

15 August 2017

volume

1072

1 reference

15 August 2017

page(s)

98-113

1 reference

Inflammatory Bowel Disease

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Inflammatory bowel disease: etiology and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

The role of Th1/Th2 polarization in mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease - focus on selective adhesion molecule inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Antibodies to interleukin 12 abrogate established experimental colitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Anti-interleukin-12 antibody for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Suppressors of cytokine signaling: Relevance to gastrointestinal function and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

GTPases and T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

How Vav proteins discriminate the GTPases Rac1 and RhoA from Cdc42.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Regulation of STAT3 by direct binding to the Rac1 GTPase

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Regulation of Bcl-xL: a little bit of this and a little bit of STAT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

Blockade of interleukin 6 trans signaling suppresses T-cell resistanceagainst apoptosis in chronic intestinal inflammation: Evidence in Crohn diseaseand experimental colitis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.001

21 January 2018

Identifiers

DOI

10.1196/ANNALS.1326.001

1 reference

15 August 2017

1 reference